Irene Defrancesco

Irene Defrancesco

Auto-generated profile, based on publicly available information

Irene Defrancesco

Unit of Bone Marrow Transplantation and Cellular Therapies, Fondazione IRCCS Policlinico San Matteo Pavia Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MFMartina Ferrante
Martina Ferrante
DFDANIELA FURLAN
DANIELA FURLAN
SZsilvia zibellini
silvia zibellini
MBMichela Borriero
Michela Borriero
CCChiara Candido
Chiara Candido
Daniela DrandiDaniela Drandi
Daniela Drandi
In IgM monoclonal gammopathies MYD88L265P is a prognostic and predictive biomarker of therapy response. MYD88L265P detection is mainly performed by allele-specific quantitative PCR (ASqPCR), however recently, droplet digital PCR (ddPCR) has been proved to be suitable for MYD88L265P screening and minimal residual disease monitoring (MRD). This study compared ASqPCR and ddPCR to define the most sensitive method for MYD88L265P detection in bone marrow (BM), peripheral blood (PB) sorted or unsorted CD19+ cells, and in plasma cell-free DNA (cfDNA). Overall, the analysis showed a good concordance rate (74%) between the two methods, especially in BM samples, while discordances (26%) were mostly in favor of ddPCR (ddPCR+ vs. ASqPCR-) and were particularly evident in samples with low mutational burden, such as PB and cfDNA. This study highlights ddPCR as a feasible approach for MYD88L265P detection across different specimen types (including cfDNA). Interestingly, its high sensitivity makes CD19+ selection dispensable. On the other hand, our results showed that MYD88L265P detection on PB samples, especially with ASqPCR, is suboptimal for screening and MRD analysis. Finally, significantly different MYD88L265P mutational levels observed between Waldenström Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance patients suggest the need for further studies in order to identify possible correlations between mutational levels and risk of progression to Waldenström.

2 June 2025 in American Journal of Hematology
Verified
Journal Article
Open access
IDIrene Defrancesco
Irene Defrancesco
VFVirginia Valeria Ferretti
Virginia Valeria Ferretti
PCPatrizia Chiusolo
Patrizia Chiusolo
DRDomenico Russo
Domenico Russo
CNChiara Nozzoli
Chiara Nozzoli
Massimo MartinoMassimo Martino
Massimo Martino
The coronavirus disease 2019 (COVID‐19) pandemic created major challenges for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Scientific societies and authorities recommended cryopreserving grafts before starting conditioning regimens, despite limited data on the clinical impact. The Italian Group for Bone Marrow Transplantation (GITMO) conducted a registry‐based study involving 3492 patients who underwent allo‐HSCT between March 2018 and September 2021. The cryopreserved cohort (n = 976) included patients who received cryopreserved grafts during the pandemic and was compared to the historical cohort (n = 2516). Graft cryopreservation was associated with a lower day 30 incidence of neutrophil and platelet engraftment (adjusted sHR = 0.8 and 0.7, p = 0.031 and p < 0.001, respectively) and delayed hematopoietic recovery. However, primary graft failure rates at day +30 were similar in the cryo and historical cohort (4% vs. 5%, respectively; p = 0.337), also after adjustment (RR = 1.19, p = 0.518). Day 100 incidence of grade II‐IV acute GVHD was comparable between the two groups (adjusted sHR = 1.2, p = 0.194). Regarding chronic GVHD incidence, we found that it was higher in patients aged < 18 years in the cryo group (adjusted sHR = 3.9, p = 0.002), but lower in those aged 18–55 years (adjusted sHR = 0.7, p = 0.008). Cumulative incidence of relapse did not differ between historical and cryo cohort (adjusted sHR 1.0. p = 0.943), as well as non‐relapse mortality (adjusted sHR 1.1, p = 0.196) and relapse‐free survival (adjusted sHR = 1.1, p = 0.197). However, a shorter overall survival was observed in the cryopreserved group (adjusted HR = 1.2, p = 0.038). Transplant centers should carefully balance the benefits and drawbacks of cryopreservation in allo‐HSCT.

25 November 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
NPNicola Polverelli
Nicola Polverelli
CZCaterina Zerbi
Caterina Zerbi
MBMaria Grazia Benevento
Maria Grazia Benevento
MAMattia Algeri
Mattia Algeri
AAAlessandra Algarotti
Alessandra Algarotti
Massimo MartinoMassimo Martino
Massimo Martino